KPF
LENZ

K2 Principal Fund’s LENZ Therapeutics LENZ Stock Holding History

K2 Principal Fund’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-138,517
Closed -$2.38M – 290
2023
Q1 		$2.38M Buy
138,517
+134,456
+3,311% +$2.17M 0.33% 75
2022
Q4 		$94.4K Buy
+4,061
New +$94.1K 0.01% 167
2022
Q3 		– Sell
-57,382
Closed -$1.1M – 362
2022
Q2 		$1.1M Buy
+57,382
New +$1.28M 0.12% 147

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

K2 Principal Fund's LENZ Position: Q2 2023 in Review

K2 Principal Fund sold out of LENZ Therapeutics (LENZ) in Q2 2023, closing a stake of 138,517 shares — an estimated $2.38M sold.

K2 Principal Fund first reported a position in LENZ in Q2 2022 and held it in 3 quarters. The position peaked at $2.38M in Q1 2023. 66 funds tracked by Wall St. Rank hold LENZ as of Q2 2023.

  • K2 Principal Fund reported no remaining LENZ Therapeutics position as of Q2 2023 after selling out during the quarter.
  • K2 Principal Fund sold 138,517 LENZ Therapeutics shares in Q2 2023, an estimated $2.38M.
  • K2 Principal Fund first reported a position in LENZ Therapeutics in Q2 2022 and held it in 3 quarters.
  • K2 Principal Fund's LENZ Therapeutics position peaked at $2.38M in Q1 2023.
  • 66 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2023.

Based on K2 Principal Fund's 13F filing for Q2 2023, filed 15 Aug 2023.